Tag Archives: Ustekinumab Biosimilar

Fresenius Kabi and Formycon Receive European Approval for Ustekinumab Biosimilar FYB202

(IN BRIEF) Fresenius Kabi, in collaboration with Formycon, has received approval from the European Commission (EC) for FYB202, a biosimilar of ustekinumab (marketed as Stelara® by Johnson & Johnson). This biosimilar is approved for the treatment of serious inflammatory diseases. … Read the full press release

Fresenius Kabi’s Ustekinumab Biosimilar Otulfi® Secures European Approval for Treating Inflammatory Diseases

(IN BRIEF) Fresenius Kabi, in partnership with Formycon AG, has received European Commission approval for Otulfi®, a biosimilar of ustekinumab. This new product, authorized for both subcutaneous and intravenous formulations, will treat inflammatory conditions such as Crohn’s disease, plaque psoriasis, … Read the full press release